Tuberculosis overview: Difference between revisions

Jump to navigation Jump to search
 
(130 intermediate revisions by 14 users not shown)
Line 1: Line 1:
<div style="-webkit-user-select: none;">
{| class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;"
|-
|{{#ev:youtube|https://https://www.youtube.com/watch?v=yR51KVF4OX0|350}}
|-
|}
__NOTOC__
{{Tuberculosis}}
{{Tuberculosis}}
{{CMG}}; '''Assistant Editor-in-Chief:''' Somal Khan
{{CMG}}; {{AE}} {{AL}}; {{JS}}; {{Ammu}}


==Overview==
==Overview==
Tuberculosis, or TB is a bacterial infection that kills 3 million people worldwide, more people than any other infection in the world. Approximately one-third of the world is infected, and 15 million people in the US. Active tuberculosis kills 60% of the time if not treated, but treatment cures 90% of patients. Most people are infected with TB have latent TB. This means that the bacteria is controlled by the body's immune system. People with latent TB do not have symptoms and cannot transmit TB to other people. However, later if the infected person has a weakened immune system (AIDS, young children, elderly, sick with other diseases, etc.), the bacteria can break out leading to active TB, or TB disease.
Tuberculosis (abbreviated as TB or Tuberculosis) is a common [[infectious disease]] caused by ''[[Mycobacterium tuberculosis]]''. Tuberculosis most commonly involves the [[lungs]] as the [[organism]] thrives in high [[oxygen]] environments, but it can also cause [[disease]] in the [[central nervous system]], the [[lymphatic system]], the [[circulatory system]], the [[genitourinary system]], [[bone]]s, [[joint]]s and even the [[skin]]. Over one-third of the world's [[population]] has been [[exposed]] to ''[[M. tuberculosis]]'', and new [[infections]] occur at a [[rate]] of one per second.  Not all individuals exposed to the [[bacterium]] develop [[clinically]] overt tuberculosis [[infection]]; in fact, [[asymptomatic]], [[Latent|latent TB]] infection discovered by [[screening]] is more [[common]]. Approximately, one in ten latent infections progresses to active ([[symptomatic]]) TB disease, which, if left untreated, carries [[mortality]] rates of up to 50%.  [[Symptoms]] include [[shortness of breath]], [[hemoptysis]], [[fever]], [[chills]], [[night sweats]], and [[weight loss]]. Several treatment regimens are available for the latent and active forms of TB. Classically, a prolonged course of 6-9 months of a single agent ([[rifampin]] or [[isoniazid]]) is administered to patients with latent TB, while a more [[aggressive]] course that consists of 4 major anti-tuberculous [[agents]] [[(rifampin]], [[isoniazid]], [[ethambutol]], [[pyrazinamide]]) is reserved for patients with active disease.


==Background==
==Historical Perspective==  
'''Tuberculosis''' (abbreviated as '''TB''' for ''tubercle bacillus'' or '''T'''u'''b'''erculosis<!-- Do not link to the genus [[Bacillus]] -->) is a common and deadly [[infectious disease]] caused by [[mycobacterium|mycobacteria]], mainly ''[[Mycobacterium tuberculosis]]''. Tuberculosis most commonly attacks the lungs (as [[Lung|pulmonary]] TB) but can also affect the [[central nervous system]], the [[lymphatic system]], the [[circulatory system]], the [[genitourinary system]], [[bone]]s, [[joint]]s and even the [[skin]]. Other mycobacteria such as ''[[Mycobacterium bovis]]'', ''[[Mycobacterium africanum]]'', ''[[Mycobacterium canetti]]'', and ''[[Mycobacterium microti]]'' can also cause tuberculosis, but these species do not usually infect healthy adults.<ref name="Harrison">{{cite book | author = Raviglione MC, O'Brien RJ | chapter = Tuberculosis | title = Harrison's Principles of Internal Medicine | editor = Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ, eds. | edition = 16th ed. | publisher = McGraw-Hill Professional | year = 2004 | pages = 953–66 | doi =10.1036/0071402357 | isbn = 0071402357 }}</ref>
*[[Tuberculosis]] has been present in humans for thousands of years.
*The earliest unambiguous detection of ''[[Mycobacterium tuberculosis]]'' was in the [[remains]] of [[bison]], dated 18,000 BC.
*[[Tuberculosis]] originated in [[cattle]] and then transferred to humans, or diverged from a common [[ancestor]].
*[[Tuberculosis]] has had many names including ''[[phthisis]]'' and ''[[Wasting]] disease''.
*Some [[hypotheses]] demonstrate that the origin of the [[genus]],  ''[[Mycobacterium tuberculosis]],'' was more than 150 million years ago.
*TB with its different names and [[presentations]] throughout its [[history]] was detected on [[skeletal]] [[deformities]] of Ancient Egyptian [[mummies]], dating back to 2400 BC.
*The first written record of TB, found in [[India]] and [[China]], dated back to 3300 and 2300 years ago.  
*In the Middle Ages as well as during the [[Renaissance]], TB was [[referenced]] to as the [[King’s]] Evil”.
*During this period if time, the [[contagious]] nature, [[pathology]] and [[anatomical]] afflictions were described.
*An English physician named [[Benjamin Marten]], supposed the anticipated [[origins]] for this [[disease]] by 1720.
*Years later, there were a number of proposed [[cures]] but the most [[significant]] [[milestone]] in the [[fight]] against TB was achieved by renowned [[scientist]], [[Robert Koch]].  
*[[Robert Koch]] discovered the ''[[Mycobacterium tuberculosis]]'' in 1882.
*In the 19th and early 20th centuries, [[tuberculosis]] caused the most widespread [[public]] concern, being considered an [[endemic]] disease of the [[urban]] poor.  
*An effective therapy became possible with the development of the [[antibiotic]] [[streptomycin]] in 1946.  
*The [[Antibiotic resistant|drug-resistant]] strains began to increase in the 1980s.


Over one-third of the world's population has been exposed to the TB bacterium, and new infections occur at a rate of one per second.<ref name="WHO2004data">[[World Health Organization]] (WHO). [http://www.who.int/mediacentre/factsheets/fs104/en/index.html Tuberculosis Fact sheet N°104 - Global and regional incidence.] March 2006, Retrieved on 6 October 2006.</ref> Not everyone infected develops the full-blown disease; [[asymptomatic]], latent TB infection is most common. However, one in ten latent infections will progress to active TB disease, which, if left untreated, kills more than half of its victims.  
==Classification==
*According to [[exposure]], [[clinical]] [[symptoms]], and [[adjunct]] [[diagnostic]] [[testing]] tuberculosis is classified into 6 main [[classes]] .
*The [[classification]] ranges from ''Class 0'', in people without previous [[exposure]] to [[TB]] and negative [[PPD|tuberculin skin testing]] and/or [[interferon-gamma release assay]]s (2 methods of [[screening]] for [[TB]]), to ''Class 3'' for [[active]] TB and ''Class 5'' for [[suspected]] TB based on [[signs]] and [[symptoms]] of the disease.
*The U.S. [[Citizenship]] and [[Immigration]] [[Services]] also made a special classification for immigrants and [[refugees]] according to the risk of infection.


In 2004, mortality and morbidity statistics included 14.6 million chronic active TB cases, 8.9 million new cases, and 1.6 million deaths, mostly in developing countries.<ref name="WHO2004data"/> In addition, a rising number of people in the developed world are contracting tuberculosis because their [[immune system]]s are compromised by [[immunosuppressive drug]]s, [[substance abuse]], or [[HIV]]/[[AIDS]].
===TB Classification System===


The rise in HIV infections and the neglect of TB control programs have enabled a resurgence of tuberculosis.<ref>{{cite journal |author=Iademarco MF, Castro KG |title=Epidemiology of tuberculosis |journal=Seminars in respiratory infections |volume=18 |issue=4 |pages=225-40 |year=2003 |pmid=14679472}}</ref> The emergence of [[Antibiotic resistance|drug-resistant]] strains has also contributed to this new epidemic with, from 2000 to 2004, 20% of TB cases being resistant to standard treatments and 2% resistant to [[Tuberculosis treatment#Treatment of MDR-TB|second-line drugs]].<ref name="MMWR2006">{{cite journal |title=Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs&mdash;worldwide, 2000&ndash;2004 |journal=MMWR Morb Mortal Wkly Rep |volume=55 |issue=11 |pages=301-5 |year=2006 |url=http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5511a2.htm | pmid = 16557213}}</ref> TB incidence varies widely, even in neighboring countries, apparently because of differences in health care systems.<ref name=Sobero_2006>{{cite journal |author=Sobero R, Peabody J |title=Tuberculosis control in Bolivia, Chile, Colombia and Peru: why does incidence vary so much between neighbors? |journal=Int J Tuberc Lung Dis |volume=10 |issue=11 |pages=1292–5 |year=2006 | pmid = 17131791}}</ref> The [[World Health Organization]] declared TB a global health emergency in 1993, and the [[Stop TB Partnership]] developed a [[Global Plan to Stop Tuberculosis]] aiming to save 14 million lives between 2006 and 2015.<ref>[[World Health Organization]] (WHO). [http://www.stoptb.org/globalplan/ Stop TB Partnership.] Retrieved on 3 October 2006.</ref>
*As per [[CDC]] ([[Centers of Disease Control and Prevention]]), the clinical classification system for [[TB]] used in the United States is based on the [[pathogenesis]] of the disease.
*This [[classification]] system provides clinicians the opportunity to keep an eye on the development of TB in their patients.
*Health care providers should follow with state and local laws and regulations requiring the reporting of TB disease.
*All persons with Class 3 or Class 5 TB should be reported directly to the local or state health department.
*A patient should not have a Class 5 classification for more than 3 months.
{| style="border: 2px solid #4479BA; align="left"
! style="width: 200px; background: #4479BA;" | {{fontcolor|#FFF|Class}}
! style="width: 300px; background: #4479BA;" | {{fontcolor|#FFF|Type}}
! style="width: 400px; background: #4479BA;" | {{fontcolor|#FFF|Description}}
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 0
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *No TB exposure<br>*Not infected
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *No history of TB exposure and no evidence of [[M. tuberculosis]] [[infection]] or [[disease]]<br>*Negative reaction to [[TST]] or [[IGRA]]
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 1
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *[[TB]] exposure<br>*No evidence of [[infection]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *History of exposure to [[M. tuberculosis]]<br>*Negative reaction to [[TST]] (Tuberculin skin tests) or [[IGRA]] (an interferon gamma release assay blood test) (given at least 8 to 10 weeks after exposure)
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 2
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *[[TB]] infection<br>*No TB disease
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *Positive reaction to TST or IGRA<br>*Negative bacteriological studies (smear and cultures)<br>*No bacteriological or radiographic evidence of active TB disease
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 3
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *[[TB]] clinically active
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *Positive culture for [[M. tuberculosis]] OR<br>*Positive reaction to [[TST]] or [[IGRA]], plus clinical, bacteriological, or radiographic evidence of current active TB
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 4
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *Previous TB disease (not clinically active)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *May have past medical history of [[TB]] disease<br>*Abnormal but stable radiographic findings<br>*Positive reaction to the [[TST]] or [[IGRA]]<br>*Negative bacteriologic studies (smear and cultures)<br>*No clinical or radiographic evidence of current active TB disease
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 5
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *[[TB]] suspected
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *[[Signs]] and [[symptoms]] of active [[TB]] disease, but medical evaluation not complete
|-
|}


==Other names==
==Pathophysiology==
In the past, tuberculosis was called '''consumption''', because it seemed to consume people from within, with a [[hemoptysis|bloody cough]], fever, [[pallor]], and long relentless wasting. Other names included '''phthisis''' (Greek for consumption) and '''phthisis pulmonalis'''; '''[[scrofula]]''' (in adults), affecting the lymphatic system and resulting in swollen neck glands; '''tabes mesenterica''', TB of the abdomen and '''[[lupus vulgaris]]''', TB of the skin; '''wasting disease'''; '''white plague''', because sufferers appear markedly pale; '''king's evil''', because it was believed that a king's touch would heal scrofula; and '''[[Pott's disease]]''', or '''gibbus''' of the spine and joints.<ref name=Britannica1911>[http://www.1911encyclopedia.org/Tuberculosis Tuberculosis] ''Encyclopedia Britannica,'' 11th ed.</ref><ref>[http://www.antiquusmorbus.com/English/English.htm Rudy's List of Archaic Medical Terms] English Glossary of Archaic Medical Terms, Diseases and Causes of Death. Accessed 09 Oct 06</ref> ''[[Miliary tuberculosis]]'' – now commonly known as '''disseminated TB'''– occurs when the infection invades the circulatory system resulting in lesions which have the appearance of millet seeds on X-ray.<ref name=Britannica1911/><ref>[http://www.nlm.nih.gov/medlineplus/ency/article/000624.htm Disseminated tuberculosis] NIH Medical Encyclopedia. Accessed 09 Oct 06</ref>
*Tuberculosis is a [[granulomatous]] [[infection]] that is chiefly transmitted through [[droplets]].
*The [https://www.wikidoc.org/index.php/Granuloma granuloma] encloses mycobacteria and prevents their spreading and facilitates immune [https://www.wikidoc.org/index.php/Immune_cell immune cell] communication.
*Within the [[granuloma]], [[CD4|T lymphocytes]] (CD4) releases [[cytokines]], such as [[interferon gamma]], that [[Activate|activates]] local [[macrophages]].
*It is [[asymptomatic]] in 90% of [[immunocompetent]] individuals.
*In [[symptomatic]] patients, it can present as [[pulmonary]] or [[extrapulmonary]] [[manifestations]]. The primary infection may turn into [[disseminated]] infection.
*[[Tuberculosis]] usually has an impact the [[progression]] of [[HIV]] if  present together. Depending on the [[age]] of the [[patient]], [[tuberculosis]] may have different [[clinical]] [[manifestations]], [[progression]], and [[prognosis]].
 
==Causes==
*'''''Mycobacterium tuberculosis''''' is the [[bacterium]] responsible for [[tuberculosis]].
*It is an [[aerobic]], [[capsule|non-encapsulated]], [[motility|non-motile]], [[acid-fast]] [[bacillus]]. 
*[[M. tuberculosis]] is one of the [[Mycobacterium]] [[tuberculosis]] [[complex]], which also includes [[bacteria]], such as [[Bovis|''M. bovis'']] and ''[[M. africanum]]''.
*The bacterium has a very slow [[rate]] of [[replication]], and its [[genetic]] [[variations]] account for the [[geographical]] [[distribution]] of different [[strains]], and are involved in [[drug resistance]]. 
*M. tuberculosis has [[tropism]] for different [[kinds]] of [[human]] [[cells]], with preference for [[Cells (biology)|cells]] of the [[lung]]. 
*It may [[infect]] different [[species]], but human [[beings]] are its frequent [[natural reservoir]].
 
==Epidemiology and Demographics==
*In 2015, about 10.4 million people developed [[symptomatic]] TB and 1.8 million [[died]] from the [[disease]].
*There were 9,421 [[reported]] [[cases]] in the [[United|United States]] in 2014  with an [[incidence]] of 3.0 per 100,000 persons.
*Since 1990, the [[mortality rate]] was steadily [[decreasing]].
*The [[prevalence]] of TB increases with [[age]] and it is higher in [[older]] men. TB is more [[Prevalence|prevalent]] in [[racial]] and [[Ethnic group|ethnic]] minorities than non-[[Hispanic]] whites. 
*[[TB]] is an major cause of [[Death-associated protein 6|death]] in people [[coinfection|coinfected]] with [[HIV]].
*A third of [[deaths]] among these [[patients]] is due to TB.
*In 2015, 60% of TB cases [[worldwide]] occurred in 6 [[countries]]: [[South Africa]], [[Indonesia]], Nigeria, Pakistan, India, and [[China]].
*The [[WHO]] has [[identified]] 24 other high-burden TB countries including Bangladesh, Congo, Columbia, Lesotho, Cambodia, Korea, [[Brazil]], Ethiopia, Myanmar, Mozambique, Thailand, [[Angola]], Zambia, Vietnam, Kenya, Central Africa, Russia, Liberia, Tanzania, Zimbabwe, Namibia, Philippines,  Sierra Leone, Papua New Guinea.
 
==Risk Factors==
*The [[risk factor]]s for the [[development]] of [[tuberculosis]] include:
**[[weakened]] [[immune system]] (patients taking [[immunosuppressive]] [[medication]] or with [[immunosuppressive]] [[diseases]], such as [[HIV]] or [[diabetes]]
**History of contact with [[infected]] patients
**Bad hygiene conditions
**Evidence of previous tuberculosis.
*[[Risk|Risk factors]] for [[multidrug-resistant TB]] include:
**Non-adherence to the [[treatment]] [[regimen]]
**Insufficient [[medication]] for that [[strain]] of [[bacteria]]
**[[Contact]] with [[patients]] with [[multidrug-resistant TB]].
 
==Screening==
*[[Screening]] for [[tuberculosis]] is generally done by using a [[mantoux tuberculin skin test]], also known as a [[tuberculin]] [[skin]] [[test]] or a [[PPD]].
*The test involves [[injecting]] a small amount of a [[purified protein derivative]] of the [[tuberculosis]] [[bacterium]] [[intradermally]] and watching for a [[reaction]] in the following days.
 
==Natural history, complications and prognosis==
*[[Tuberculosis]] has been [[classified]] as a [[primary]] or [[secondary]] (post-primary) [[infection]].
*It can have [[pulmonary]] and extra pulmonary [[manifestations]] as well as severe [[parenchymal]], vascular, pleural, and chest wall complications.
*Pulmonary complications include [[pleural effusions]], [[cavitations]], [[lymphadenopathy]], airway obstruction, [[pneumonia]] and [[bronchietasis|bronchiectasis]].
*The [[hematogenous]] [[dissemination]] of [[infection]] can lead to [[miliary tuberculosis]].
*The post-primary [[infection]] can be due to a [[recent]] infection or [[reactivation]] of an old infection. Without [[treatment]], 1/3 of patients with active [[tuberculosis]] dies within 1 year of the [[diagnosis]], and more than 50% during the first 5 years.
*But with early [[diagnosis]] and [[treatment]], it has a good [[prognosis]].
 
==Diagnosis==
===History and Symptoms===
*The [[general]] [[symptoms]] of tuberculosis include [[weakness]], [[weight loss]], [[fever]], and [[night sweats]].
*[[Symptoms]] of pulmonary tuberculosis include [[cough]], [[chest pain]], and [[hemoptysis]]. 
*[[Tuberculosis]] is particularly difficult to [[diagnose]] in [[children]], as these may not present with [[Common Atrium|common]] [[Findings on urinalysis|findings]].
 
===Physical Examination===
*A [[physical]] [[examination]] can give an [[overview]] about the [[Overall|general]] [[condition]] and other [[factors]] that may influence the [[tuberculosis]] response to treatment, such as [[HIV]] [[infection]] or other diseases.
*The most common [[physical]] findings include [[fever]], [[decreased breath sounds]], [[tachypnea]] and [[tachycardia]]. 
*Physical findings will depend on the location of the tuberculosis infection.
 
===Laboratory findings===
*[[Routine]] [[laboratory]] exams are usually in the [[normal]] [[ranges]].
*The presence of [[acid-fast-bacilli]] ([[AFB]]) on a [[sputum]] [[smear]] or another [[specimen]] often indicates TB disease and a positive [[culture]] for [[M. tuberculosis]] confirms the [[diagnosis]]. 
*Other [[laboratory]] tests include [[peritoneal fluid]] or [[CSF]] analysis, [[urinalysis]], and [[Interferon]]-[[Gamma]] [[release]] [[assays]].
 
===Electrocardiogram===
*[[Echocardiography]] or [[Ultrasound]] can be helpful in patients who develop [[pericardial effusion]] secondary to TB. In rare occasions TB may lead to [[congestive heart failure]], in which case [[echocardiograph]] may also help in the diagnosis. 
*Common findings in [[CHF]] on the [[echocardiogram]] include: [[hypokinesia]]; [[valvular insufficiency]]; and [[enlargement]] of all [[heart]] [[chambers]].
 
===Chest X-Ray===
*A [[chest X-ray]] is one of the important [[diagnostic]] tools in [[tuberculosis]].
*A [[chest]] [[radiograph]] may be used to rule out the possibility of [[pulmonary]] TB in a person who are [[symptomatic]] or had a positive reaction to a [[tuberculin test]] or QFT-G and no symptoms of the disease.
*The findings on chest x-ray can be divided into [[parenchymal]] and [[pleural]].
*The early [[Parenchyma|parenchymal]] findings can be infiltrated, and cavity.
*A healed tuberculotic lesion can present as [[fibrosis]], and [[calcification]].
*[[Pleural]] [[lesions]] in form of [[pleural effusion]] can also be seen.
*An [[advanced]] [[tuberculosis]] lesion can present a combination of these early lesions and termed [[fibrocavitary]] [[lesions]].
 
===CT===
*The majority of patients with [[pulmonary]] [[tuberculosis]] will have [[abnormal]] findings in a [[chest]] [[CT]], which include [[micronodules]], [[interlobular]] [[septal]] [[thickening]], [[cavitation]] and [[Consolidation (medicine)|consolidation]]. 
*[[CT scan]] is more [[sensitive]] than an [[X-ray]] to detect [[lymphadenopathy|lymphadenopathies]].
 
===MRI===
*MRI is used for the [[Assessment and Plan|assessment]] of [[extrapulmonary]] tuberculosis, such as [[Tuberculous meningitis|CNS tuberculosis]], [[Pott's disease]], and [[parotid gland]] tuberculosis.
 
===Echocardiography or Ultrasound===
*[[Echocardiography]] or [[Ultrasound]] can be helpful in patients who develop [[pericardial effusion]] secondary to TB.
*In [[rare]] occasions TB may lead to [[congestive heart failure]], in which case [[echocardiograph]] may also help in the [[diagnosis]]. 
*Common findings in [[CHF]] on the [[echocardiogram]] include: [[hypokinesia]]; [[valvular]] [[insufficiency]]; and enlargement of all [[heart chambers]].
 
===Other Imaging findings===
*The [[abreugraphy]] is a smaller [[variant]] of the [[chest X-ray]] that allows the [[Identification of sites|identification]] of [[lung]] [[abnormalities]] that may suggest the [[diagnosis]] of TB. 
*With the decrease of [[incidence]] of TB, the [[abreugraphy]] is no longer recommended in most countries for low-risk populations. 
*However, depending on the [[screening]] resources of each country, it may be used for the [[screening]] of [[high-risk]] groups, such as [[HIV]]-positive patients and [[alcoholics]].
 
===Other Diagnostic Studies===
*Because of difficulties with the [[Tuberculin skin test]], many [[laboratory]] methods of [[diagnosis]] are [[emerging]].
 
==Treatment==
===Medical Therapy===
*If there is a high [[probability]] of [[infection]], presumptively [[treat]] the patient even if the stain is [[negative]], while waiting for the [[culture]] [[results]]. 
*The patient should be brought back in a few weeks. 
*Patients usually feel better a few weeks post-treatment.
*Patients must be [[monitored]] for [[Adverse effect (medicine)|adverse effects]] and treatment [[failure]].  
*In the U.S., all TB is tested for [[drug resistance]].
 
====Special conditions====
*[[Medical]] [[therapy]] for tuberculosis in special conditions include [[HIV]] co-infection and extra pulmonary [[manifestations]].
*Different approaches are taken for [[patients]] taking [[AIDS antiretroviral drugs|ART]] and those who do not take [[AIDS antiretroviral drugs|ART]].  
*Although [[World Health Organization|WHO]] recommends the same drug regimen for pulmonary and extrapulmonary [[manifestations]], various stages of [[skeletal]] tuberculosis are managed differently.  
*For patients with [[renal]] or [[liver]] diseases, the first line of drugs are substituted with second-line drugs to prevent [[Complication (medicine)|complications]].
 
====Drug-resistant====
*[[Drug resistance|Drug-resistant]] tuberculosis is caused by M. tuberculosis [[organisms]] that are [[resistant]] to at least one first-line anti-TB drug.
*[[Multi-drug-resistant tuberculosis|Multidrug-resistant TB]] (MDR TB) is resistant to more than one [[anti-TB drug]] and at least [[isoniazid]] ([[INH]]) and [[rifampin]] ([[RIF]]).
*Treatment should be started with an [[empirical]] treatment of at least 4 drugs based on expert advice as soon as [[Multi-drug-resistant tuberculosis|drug-resistant TB]] disease is suspected.
 
====Children====
*[[Tuberculosis]] in children aged 15 years or younger is a [[public health problem]] of special [[significance]] because it is a marker for recent [[transmission]] of TB. *Infants and young [[children]] are more likely to develop life-threatening forms of tuberculosis, such as [[miliary TB]] or [[TB meningitis]].
*[[Screening]] in children is very important, as the [[clinical manifestations]] are usually poor or [[non-specific]]. 
*History of close contact with tuberculosis patients has an important role in the [[diagnosis]] of TB in children. 
*The [[treatment]] is similar to adults, with adjusted [[dosing]] according to the child's weight.
 
===Surgery===
*[[Surgery]] may be necessary, especially to [[Drain (surgery)|drain]]  [[abscess]]es , [[empyema]], [[venticular shun]]<nowiki/>t in [[tubercular meningitis]], [[surgical resection]] of [[tissues]] affected in [[abdominal tuberculosis]], stabilize the [[spine]] in case of [[Pott's disease]], [[lobectomy]], [[pneumonectomy]], [[pericardiocentesis]] or surgical repair of [[pericardium]].
 
===Primary Prevention===
*[[Primary prevention]] in tuberculosis is targeted to avoid disease [[Transmission (medicine)|transmission]] and infection of [[healthy]] individuals. The [[BCG]] [[vaccine]] is used in children [[Susceptible individual|susceptible]] to TB infections, such as children living in [[Endemic (epidemiology)|endemic]] areas or having [[close contact]] with a confirmed [[case]] of TB
*Several [[Preventive medicine|preventive]] [[measures]] are used to avoid the [[transmission]] of the [[mycobacteria]], such as [[respiratory]] [[Isolation (health care)|isolation]], use of respiratory [[masks]] among [[health-care professionals]], and advising [[respiratory hygiene]] and [[cough]] etiquette.
 
===Secondary Prevention===
*[[Secondary prevention]] for tuberculosis includes [[methods]] for [[screening]] and early [[diagnosis]], such as [[tuberculin skin test]] (TST) and [[IGRAs]]; and to guarantee the correct [[treatment]] [[regimen]] at the right time to prevent [[disease]] [[progression]].
 
===Cost effectiveness of therapy===
*Treatment of [[tuberculosis]] must be [[analyzed]] for relative [[Cost-effectiveness|cost]] [[effectiveness]] of [[inpatient]] and [[outpatient]] models of [[care]] as it will [[benefit]] regions where [[tuberculosis]] is highly [[prevalent]].  
*Unless there is severe [[Complication (medicine)|complications]] it is highly recommended to treat the TB patient in [[ambulatory care]] rather than [[inpatient]] services.
 
===Future or investigational therapy===
*Since new [[drug-resistant tuberculosis]] has been emerging, the role of future [[therapies]] is [[vital]] in curbing [[outbreaks]].  
*The new [[:Category:Drugs|drugs]] should be more effective than the current [[regimen]] and a few drugs in [[clinical]] trials have been showing good [[results]].


==References==
==References==
{{reflist|2}}
{{WH}}
 
{{WS}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:Bacterial diseases]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Pulmonology]]
[[Category:Pulmonology]]{{Reflist|2}}
[[Category:Infectious disease]]
[[Category:Overview complete]]

Latest revision as of 21:55, 26 June 2021

https://https://www.youtube.com/watch?v=yR51KVF4OX0%7C350}}

Tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Children

HIV Coinfection

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special Conditions
Drug-resistant

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberculosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberculosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberculosis overview

CDC on Tuberculosis overview

Tuberculosis overview in the news

Blogs on Tuberculosis overview

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Tuberculosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]; João André Alves Silva, M.D. [3]; Ammu Susheela, M.D. [4]

Overview

Tuberculosis (abbreviated as TB or Tuberculosis) is a common infectious disease caused by Mycobacterium tuberculosis. Tuberculosis most commonly involves the lungs as the organism thrives in high oxygen environments, but it can also cause disease in the central nervous system, the lymphatic system, the circulatory system, the genitourinary system, bones, joints and even the skin. Over one-third of the world's population has been exposed to M. tuberculosis, and new infections occur at a rate of one per second. Not all individuals exposed to the bacterium develop clinically overt tuberculosis infection; in fact, asymptomatic, latent TB infection discovered by screening is more common. Approximately, one in ten latent infections progresses to active (symptomatic) TB disease, which, if left untreated, carries mortality rates of up to 50%. Symptoms include shortness of breath, hemoptysis, fever, chills, night sweats, and weight loss. Several treatment regimens are available for the latent and active forms of TB. Classically, a prolonged course of 6-9 months of a single agent (rifampin or isoniazid) is administered to patients with latent TB, while a more aggressive course that consists of 4 major anti-tuberculous agents (rifampin, isoniazid, ethambutol, pyrazinamide) is reserved for patients with active disease.

Historical Perspective

Classification

TB Classification System

  • As per CDC (Centers of Disease Control and Prevention), the clinical classification system for TB used in the United States is based on the pathogenesis of the disease.
  • This classification system provides clinicians the opportunity to keep an eye on the development of TB in their patients.
  • Health care providers should follow with state and local laws and regulations requiring the reporting of TB disease.
  • All persons with Class 3 or Class 5 TB should be reported directly to the local or state health department.
  • A patient should not have a Class 5 classification for more than 3 months.
Class Type Description
0 *No TB exposure
*Not infected
*No history of TB exposure and no evidence of M. tuberculosis infection or disease
*Negative reaction to TST or IGRA
1 *TB exposure
*No evidence of infection
*History of exposure to M. tuberculosis
*Negative reaction to TST (Tuberculin skin tests) or IGRA (an interferon gamma release assay blood test) (given at least 8 to 10 weeks after exposure)
2 *TB infection
*No TB disease
*Positive reaction to TST or IGRA
*Negative bacteriological studies (smear and cultures)
*No bacteriological or radiographic evidence of active TB disease
3 *TB clinically active *Positive culture for M. tuberculosis OR
*Positive reaction to TST or IGRA, plus clinical, bacteriological, or radiographic evidence of current active TB
4 *Previous TB disease (not clinically active) *May have past medical history of TB disease
*Abnormal but stable radiographic findings
*Positive reaction to the TST or IGRA
*Negative bacteriologic studies (smear and cultures)
*No clinical or radiographic evidence of current active TB disease
5 *TB suspected *Signs and symptoms of active TB disease, but medical evaluation not complete

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Natural history, complications and prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory findings

Electrocardiogram

Chest X-Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special conditions

  • Medical therapy for tuberculosis in special conditions include HIV co-infection and extra pulmonary manifestations.
  • Different approaches are taken for patients taking ART and those who do not take ART.
  • Although WHO recommends the same drug regimen for pulmonary and extrapulmonary manifestations, various stages of skeletal tuberculosis are managed differently.
  • For patients with renal or liver diseases, the first line of drugs are substituted with second-line drugs to prevent complications.

Drug-resistant

Children

Surgery

Primary Prevention

Secondary Prevention

Cost effectiveness of therapy

Future or investigational therapy

References

Template:WH

Template:WS